Fusion of the androgen-regulated gene, TMPRSS2, with ERG occurs in up to 60% of prostate cancers and is likely to account for the majority of ETS oncogene rearrangements in prostate cancer (Attard et al, 2008). This evidence concerns the gene TMPRSS2 and prostate carcinoma.